India, July 19 -- Investing in biotech stocks is a gamble, especially when it involves clinical-stage companies with no stable revenue streams. In most cases, the clinical trial readouts and regulatory news are make-or-break events that could have a significant impact on the stock prices.
As legendary stock trader Jesse Livermore once advised, "Cut your losses short and let your winners run", a principle that is particularly relevant in the high-stakes arena of biotech investing.
The following are some of the biotech stocks that hit new 52-week highs on Friday (July 18, 2025).
Shares of Atai Life Sciences N.V. (ATAI) touched a new 52-week high of $3.35 on Friday as this clinical-stage biopharmaceutical company awaits a key data readout i...